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Abstract: A key aim of biocatalysis is to mimic the ability of
eukaryotic cells to carry out multistep cascades in a controlled
and selective way. As biocatalytic cascades get more complex,
reactions become unattainable under typical batch conditions.
Here a number of continuous flow systems were used to
overcome batch incompatibility, thus allowing for successful
biocatalytic cascades. As proof-of-principle, reactive carbonyl
intermediates were generated in situ using alcohol oxidases,
then passed directly to a series of packed-bed modules con-
taining different aminating biocatalysts which accordingly
produced a range of structurally distinct amines. The method
was expanded to employ a batch incompatible sequential
amination cascade via an oxidase/transaminase/imine re-
ductase sequence, introducing different amine reagents at each
step without cross-reactivity. The combined approaches allo-
wed for the biocatalytic synthesis of the natural product 4O-
methylnorbelladine.
Introduction
Multi-step synthesis in biocatalysis has been made more
efficient through the utilization of enzymatic cascades. No
longer are reactions limited by intermediate isolation, thus
significantly reducing time and waste.[1, 2] The design of mul-
tienzyme systems has provided convenient syntheses of
a number of high value compounds and are now seen as the
method of choice in implementing biocatalytic reactions.[3,4]
Computer-aided synthesis planning (CASP) is also poised to
revolutionize biocatalytic synthesis planning, allowing in sili-
co prediction of novel biocatalytic cascades.[5] Nevertheless,
while biocatalytic cascades are increasingly considered as the
method of choice for more complex syntheses, there are still
limitations to one-pot systems due to incompatible enzyme/
substrate combinations.
Flow chemistry has seen rapid development in recent
years, with the potential to improve about 50 % of chemical
processes.[6] Small scale flow systems can be translated into
larger scale production with minimal optimization as the sy-
stems can be run for longer to increase productivity, a luxury
not afforded in batch processes which need to be scaled up.[7,8]
Another advantage is that continuous flow systems can be
composed of different modules (different reactor types),
which can enable the combination of a broad range of che-
mistries that are incompatible under batch conditions (Fig-
ure 1).[9] Further to this, the utilization of continuous flow
systems facilitates the integration of several reaction steps
resulting in telescoped synthetic sequences.[10]
Issues that arise with analytical biotransformations not
being translatable to scale or different biocatalytic reaction
types being incompatible, has led to the emergence of conti-
nuous flow biocatalysis as a favorable option to alleviate these
issues.[11] Operating under a continuous regime allows for
greater control of reaction conditions as well as providing
opportunities for inline analysis and purification, as well as
Figure 1. Advanced compartmentalized continuous flow systems can
be used to overcome incompatible enzyme combinations/chemistries
can deliver the lab-based technological advancement necessary to fully
realize this transformation.
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automation.[12,13] Most flow biocatalysis systems utilize im-
mobilized enzymes, which vastly improves reusability and
often increases thermal stability and solvent tolerance.[14–16]
The combination of immobilization and continuous flow
reactors means that enzymes can be compartmentalized and
segregated, allowing access to previously incompatible reac-
tions in sequential reactor modules. Herein, efforts to exploit
the power of biosynthetic cascades with a continuous, com-
partmentalization approach containing multiple reactor types
and a combination of free and immobilized enzyme are de-
scribed. Issues of cross reactivity and reaction incompatibility
in linear enzymatic cascades are addressed whilst also sho-
wing compartmentalized flow systems can be used to over-
come metabolic flux issues associated with in vitro cascades
(Figure 1).[17] The aim was to adopt a modular approach using
standard laboratory equipment to generate versatile systems
which enable access to a broad range of chemistries.
Results and Discussion
The reaction cascades described here started with the
generation of aldehydes from stable and commercially avail-
able alcohols. As aldehydes are versatile yet unstable inter-
mediates, it was thought a continuous flow system that gen-
erated this group in situ at high concentrations could allow for
a range of subsequent enzymatic modifications. Biocatalytic
oxidations are fundamental in transitioning to a bio-based
economy, in particular the use of oxidases which carry out
selective oxidation using molecular oxygen as the sole oxi-
dant.[18,19] To overcome potential limitations of oxygen con-
centration, a previously described multipoint injection reactor
(MPIR) was employed; it was shown to greatly improve the
productivity of oxidase biocatalysts by negating low aqueous
oxygen availability through in situ biocatalytic generation
from hydrogen peroxide (Table 1).[20–22] An engineered cho-
line oxidase (AcCO6) was initially chosen as an ideal biocat-
alyst to test in the MPIR due to its broad substrate scope and
as it has been applied in biocatalytic cascades.[23, 24] Using the
MPIR, AcCO6 productivity was vastly improved for the
oxidation of a number of aromatic and aliphatic primary al-
cohols with a 58 fold improvement in space time yield and 4
fold improvement in productivity in the oxidation of pheny-
lethanol (see the Supporting Information). The bio-oxida-
tions were further optimized to ensure no over-oxidation to
the corresponding acid was observed, an issue associated with
batch reactions and a previous flow report for this enzyme.[14]
Following the successful implementation of the MPIR for
the generation of aldehydes, the system was expanded by
carrying out subsequent continuous bio-reductive aminations.
Amines are important molecules in synthetic chemistry, with
a significant proportion of the reactions performed by medi-
cinal chemists reported to be associated with amino-group
chemistry.[25] Biocatalytic amine synthesis has been advanced
by transaminases and imine reductases/reductive aminases
(IREDs/RedAms), with the use of aminating biocatalysts
providing selective and sustainable options for the synthesis
of chiral amines.[26, 27] One of the most frequently applied
aminating enzymes in flow is transaminase.[28, 29] Therefore,
the transaminase from Bacillus megaterium (BmTA) was
immobilized and loaded it into a packed-bed reactor.[23,30]
This was connected to the output of the MPIR (with inline
mixing via a micro static mixer), generating an MPIR-packed
bed system (MPBS). Pleasingly, full conversion to the cor-
responding primary amine 2 was achieved at steady state and
maintained for four hours (STY: 1.58 gL1 h1).
For the generation of secondary amines such as 3 from
aldehyde 1, RedAm and glucose dehydrogenase (GDH)
combinations can be used and have also been demonstrated in
flow systems previously.[14, 31, 32] Here, the reductive aminase
from Ajellomyces dermatitidis (AdRedAm, 200 mg, 10 wt%)
and the GDH from Bacillus megaterium (BsGDH, 10 mg,
10 wt %) were immobilized and both loaded into a packed
bed reactor. Pleasingly, this also gave full conversion of the in
situ generated hydrocinnamaldehyde 1 to the corresponding
N-allyl amine 3 at steady state which was maintained for four
hours (STY: 2.1 gL1 h1) (Table 1).
Following the optimization of AcCO6-amination cascades
in continuous flow, the combination of previously batch-in-
compatible enzyme systems was investigated. Galactose ox-
idase (GOase), a copper-dependent alcohol oxidase, has been
shown to be a useful tool in biocatalysis with a number of
variants displaying a broad substrate scope.[33–35] Using GOase
instead of choline oxidase would lead to a panel of benzylic
amines as shown in Scheme 1. However, due to the reactive
copper center in GOase, amines can inhibit the biocatalyst
meaning one-pot batch reactions are not feasible with ami-
nating enzymes. Indeed, when the cascades were carried out
in batch, performance as expected was poor, with no ob-
servable conversion to the corresponding amines (see Sup-
porting Information).
To overcome these issues the use of compartmentalized
MPBS was investigated. Pleasingly, extremely efficient cas-
cades were observed with > 95% conversion achieved in the
Tabelle 1: Representation of the MPIR-packed bed continuous flow sy-
stem for the biocatalytic synthesis of amines from alcohols.[a]
[a] Key: *Steady state conversions determined by GC-FID and compared
to chemical standards.
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reductive amination of five benzaldehydes 4 (generated in
situ by GOase in the MPIR, Scheme 1), using the trans-
aminase from Vibrio fluvialis (VfTA) and AdRedAm to
generate the primary 5 and secondary amines 6, respectively.
Fresh samples of immobilized enzyme preparations were used
for each of the described systems to avoid the need to study
long term stability between experiments. Importantly, due to
immobilization of the enzymes, several substrates could be
screened using the same columns. This approach efficiently
surveyed the activity of VfTA and AdRedAm in the reductive
amination of the benzaldehyes 4a–e (20 mM: five or 10 equiv.
amine). A total system residence time of < 38 mins was
enough to obtain > 90% conversion in all instances. A panel
of 10 primary 5a–e/secondary amines 6a–e (10 mM) were
generated merely by changing the flow path and the initial
benzyl alcohol, an approach far less time consuming than the
preparation of individual batch reactions and enzyme pre-
parations. To further increase efficiency and automation,
three-way switching valves (including
a retrofitted HPLC waste valve) were
added to the system (Scheme 1); this
enabled exquisite control of the flow
path without the laborious need of
changing lines or columns. Using this
approach, the system could be quickly
switched between „RedAm“ and „TA“
flow paths without intermittent was-
hing steps, thus vastly improving ef-
ficiency. The same approach was also
used for substrate feeding to the MPIR
again greatly improving the efficiency
of the system. These cascades represent
the first demonstration of continuous
biocatalyst substrate screening. This
streamlined flow system has the po-
tential to complement current high
throughput biocatalytic screening me-
thods in future,[36] and ultimately faci-
litate automation for biocatalytic cas-
cade discovery in a highly efficient
manner.
Following the successful imple-
mentation of the oxidase-bioamination
cascades, the wide scope of the system
was demonstrated with in situ amine
donor generation in a TA-RedAm
cascade (Table 2). Combinations of TA
and RedAm/IRED in batch are not
compatible because both enzymes use
amine substrates with potential for
cross reactivity. Hence, the in situ
generation of primary amines by TAs
for use in subsequent reductive ami-
nations by RedAm/IRED has yet to be
explored. For the initial flow bio-
amination cascade, BmTA and AdRe-
dAm (with BsGDH) were immobilized
on EziG amber support (200 mg
10 wt %) and placed in separate packed
bed reactors, to prevent the previously mentioned potential
issues for cross amination. Initially, a solution containing
butanal (40 mM), racemic alanine (400 mM) and PLP (1 mM)
was passed through the TA module, achieving full conversion
to butylamine 7 at steady state with a residence time of
12 minutes. The effluent of this reaction was mixed via a mi-
crostatic mixer (see Supporting Information) with another
solution containing cyclohexanone (10 mM), NADP+ (1 mM)
and glucose (50 mM). Initial results with AdRedAm showed
about 20 % conversion at steady state, with four equivalents
of amine 7 necessary (20 mM butylamine 7, and 5 mM ketone
in RedAm module). To further improve the productivity of
this reaction a more suitable RedAm was selected from
a metagenomics panel.[37] The RedAms were identified using
a previously described screen containing 384 different enzy-
mes, which gives a colourimetric indication of activity using
a coupled diaphorase system (see supporting information and
references).[37,38] For the generation of N-butylcylohexlya-
Scheme 1. GOase M3-5 and AdRedAm/VfTA were applied in the MPBS continuous flow system
and used for cascade screening. Steady state conversions determined by GC-FID analysis. Triang-
le in circle: pump; cross in circle: mixing valve.
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mine 10, IR-79 was selected and immobilized on the EziG
amber support (100 mg, 10 wt%), with 85% conversion to the
secondary amine 10 observed and
maintained for three hours at stea-
dy state (Table 2). This represented
a total system residence time of 21
mins (STY: 1.87 gL1 h1), and only
required two equivalents of butyla-
mine 7 (20 mM butylamine and
10 mM ketone in RedAm module).
This approach was expanded to
generate N-(2-phenyl)ethyl cy-
clohexylamine 11 using another
metagenomic RedAm (IR-23),
again only requiring two equiva-
lents of amine with a system res-
idence time of 24 mins (STY:
2.53 gL1 h1). A third approach
was then used to generate N-ben-
zylcyclohexylamine 12 with the
transaminase from Pseudomonas
putida (PpTA)[39] mediated trans-
amination of benzaldehyde follo-
wed by reductive amination with
cyclohexanone using IR-79. Plea-
singly 95% conversion to 12 was
achieved and maintained for four
hours with a system residence time of 24 mins (STY:
2.24 gL1 h1). Again, the implementation of several swit-
ching valves allowed rapid change of flow path and enabled
the generation of three RedAm products (10, 11, 12) without
isolation or purification of any intermediates.
De novo designed biocatalytic cascades are often limited
to 2–4 steps due to incompatibility issues as discussed above,
which become more limiting as the number of steps increases.
After demonstrating that MPBS could over-come these is-
sues, a compartmentalized six-enzyme cascade was targeted,
highlighting that multiple reactor technologies can be com-
bined to enable previously inaccessible reaction sequences. A
synthetic sequence that was able to convert primary alcohols
into amines via an oxidase-TA sequence, which could then be
used as the amine substrate for a RedAm reaction was envi-
saged (Table 3). Using the compartmentalized MPBS, Ac-
CO6 efficiently oxidized phenylethanol (120 mM). The res-
ulting aldehyde 14 was mixed with racemic alanine (400 mM)
and PLP (1 mM) via a microstatic mixer, which then passed
through immobilized BmTA forming 2-phenylethylamine 8.
The effluent from this reaction was mixed with a RedAm line
(glucose (50 mM), NADP+ (1 mM), cyclohexanone (10 mM))
and passed through immobilized IR-79 to quantitatively
generate 11 under continuous conditions. Pleasingly, amine
donors were generated in two biocatalytic steps from the al-
cohols, which then fed directly into the RedAm reactors that
successfully utilized the in situ generated amine substrates.
All three examples reached steady state conversions of
> 90%.
To highlight the benefits of this system in target synthesis,
a continuous biocatalytic synthesis of 4O-methylnorbelladine
17 via an Oxidase-RedAm cascade was designed
(Scheme 2).[5] 4O-Methylnorbelladine is an important pre-
cursor in the synthesis of a number of pharmacologically ac-
Tabelle 2: Transaminase-RedAm cascades.[a]
[a] Cascades were applied in a multi packed-bed reactor system with
switching valves enabling efficient control of flow path. Conversions to
primary and secondary amines were calculate by comparison of GC-FID
spectra with product standards. Key: *Reductive amination carried out
by AdRedAm.
Tabelle 3: A six enzyme continuous cascade used for the synthesis of asymmetric amines.[a]
[a] Conversion was determined by GC-FID.
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tive alkaloid scaffolds, such as the dementia drug galanta-
mine.[40, 41] For this cascade, it was thought tyramine 16 could
be generated via a continuous oxidase-TA cascade. Choline
oxidase activity was tested against tyrinol in the MPIR. The
resulting biogenic aldehyde is a key intermediate in the bio-
synthesis of benzylisoquinoline alkaloids and often requires
multistep syntheses.[42, 43] Despite the biooxidation proving
highly efficient (120 mM substrate loading; > 90 % conver-
sion; STY: 8.37 gL1 h1; productivity: 5.1 gproduct genzyme
1) ty-
ramine was commercially available at a lower cost than the
alcohol so this step was not necessary.
For the reductive amination of isovanillin and tyramine
16, the previously described high throughput colorimetric
assay was used to identify potential RedAms.[38] From this
screen IR-80 was selected and the reaction validated with an
analytical scale biotransformation. The product 17 was found
to be insoluble in aqueous buffer and proved difficult to
analyze by HPLC. As an alternative, the crude biotransfor-
mation was filtered, and the residue suspended in DMSO/
MeOH for MALDI analysis with an observed m/z of 274.2
corresponding to the protonated adduct of the product 17 (see
Supporting Information). Encouraged by this result, IR-80
was immobilized on EziG amber (150 mg, 10 wt %) for
translation into continuous flow (Scheme 2). To implement
a cascade for this synthesis, a GOase M3-5 (5 mgmL
1) me-
diated biooxidation of isovanilyl alcohol 15 (30 mM) was
carried out in the MPIR. The effluent was mixed with the
RedAm feed (tyramine 16 (50 mM), NADP+ (0.1 mM) and
glucose (50 mM)) which was flowed through an IR-80 module
to quantitatively generate 17 for four hours with a system
residence time of 36 min (STY: 2.26 gL1 h1). Filtration of
the effluent allowed recovery of the excess tyramine and
provided a simple purification method for the isolation of 17.
Conclusion
For the first time it has been shown that previously in-
compatible enzyme cascades can be run continuously, greatly
improving the metrics (up to 58-fold for STY and 4-fold for
enzyme productivity) when compared to the equivalent batch
reactions. This system is extremely versatile with several en-
zyme combinations tested that enabled the generation of
a range of amine intermediates. The reactors were also ex-
tended to demonstrate proof-of-concept, high throughput
reaction screening in continuous flow. A continuous synthesis
of the biologically relevant molecule 4O-methylnorbelladine
was also successfully demonstrated. Using a continuous ap-
proach allows many additional benefits to those discussed
here to further improve biocatalytic reaction efficiency. In
particular, recycling of co-factors is made operationally more
simple with flow systems which significantly reduces the
economic impact.[29, 44] Furthermore, combination with auto-
mated high throughput biocatalyst screening,[36] and computer
aided synthesis planning,[5] paves the way for fully auto-
nomous biocatalytic synthesis.
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